Primary HPV and Molecular Cervical Cancer Screening in US Women Living With Human Immunodeficiency Virus
暂无分享,去创建一个
A. Adimora | K. Anastos | P. Castle | M. Fischl | I. Eltoum | S. Shrestha | X. Xue | H. Minkoff | J. Leider | L. Flowers | G. D’Souza | Xianhong Xie | L. Sanchez-Keeland | L. Rahangdale | C. Colie | S. Massad | Catalina Ramirez | I. Ofotokun | A. Hessol | H. Einstein | Rodney L. Wright | D. Burk | O. Díaz | J. Keller | D. Strickler | M. Atrio | Huchko | M. Palefsky | Ighovwhera Ofotokun
[1] J. Cuzick,et al. Relationships of p16 Immunohistochemistry and Other Biomarkers With Diagnoses of Cervical Abnormalities: Implications for LAST Terminology. , 2019, Archives of pathology & laboratory medicine.
[2] K. Anastos,et al. Racial differences in human papilloma virus types amongst United States women with HIV and cervical precancer , 2018, AIDS.
[3] K. Anastos,et al. Methylation of High-Risk Human Papillomavirus Genomes Are Associated with Cervical Precancer in HIV-Positive Women , 2018, Cancer Epidemiology, Biomarkers & Prevention.
[4] L. Learman,et al. Screening for Cervical Cancer: New Tools and New Opportunities. , 2018, Journal of the American Medical Association (JAMA).
[5] Gina Wingood,et al. Cohort Profile: The Women's Interagency HIV Study (WIHS). , 2018, International journal of epidemiology.
[6] E. Engels,et al. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. , 2017, The lancet. HIV.
[7] B. Richardson,et al. Role of p16 testing in cervical cancer screening among HIV-infected women , 2017, PloS one.
[8] J. Cuzick,et al. A comparison of different human papillomavirus tests in PreservCyt versus SurePath in a referral population—PREDICTORS 4 , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[9] P. Benedetti Panici,et al. Management of HPV-Related Cervical Disease: Role of p16INK4a Immunochemistry. Review of the Literature , 2016, Tumori.
[10] Y. Qiao,et al. Effectiveness of novel, lower cost molecular human papillomavirus‐based tests for cervical cancer screening in rural china , 2016, International journal of cancer.
[11] J. Palefsky,et al. Association of cervical precancer with human papillomavirus types other than 16 among HIV co-infected women. , 2016, American journal of obstetrics and gynecology.
[12] K. Anastos,et al. Cervical Precancer Risk in HIV-Infected Women Who Test Positive for Oncogenic Human Papillomavirus Despite a Normal Pap Test. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] S. Wacholder,et al. HPV16 methyl‐haplotypes determined by a novel next‐generation sequencing method are associated with cervical precancer , 2015, International journal of cancer.
[14] E. J. Mayeaux,et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. , 2015, Gynecologic oncology.
[15] J. Palefsky,et al. Cervical human papillomavirus testing to triage borderline abnormal pap tests in HIV-coinfected women. , 2014, AIDS.
[16] R. Pfeiffer,et al. Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States , 2014, AIDS.
[17] Richard D Moore,et al. Invasive Cervical Cancer Risk Among HIV-Infected Women: A North American Multicohort Collaboration Prospective Study , 2013, Journal of acquired immune deficiency syndromes.
[18] K. Anastos,et al. Risk of cervical precancer and cancer among HIV-infected women with normal cervical cytology and no evidence of oncogenic HPV infection. , 2012, JAMA.
[19] Thomas C Wright,et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. , 2011, The Lancet. Oncology.
[20] Mark Schiffman,et al. The Accuracy of Colposcopic Grading for Detection of High-Grade Cervical Intraepithelial Neoplasia , 2009, Journal of lower genital tract disease.
[21] J. Goedert,et al. Cancer risk in people infected with human immunodeficiency virus in the United States , 2008, International journal of cancer.
[22] Diane Solomon,et al. Number of Cervical Biopsies and Sensitivity of Colposcopy , 2006, Obstetrics and gynecology.
[23] R. DeSalle,et al. The carcinogenicity of human papillomavirus types reflects viral evolution. , 2005, Virology.
[24] R. Alvarez,et al. High-Risk Human Papillomavirus and Cervical Intraepithelial Neoplasia at Time of Atypical Squamous Cells of Undetermined Significance Cytologic Results in a Population with Human Immunodeficiency Virus , 2004, Journal of lower genital tract disease.
[25] Joseph Feldman,et al. The Women's Interagency HIV Study , 1998 .
[26] Chyke A Doubeni,et al. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement , 2018, JAMA.
[27] P. Giorgi Rossi,et al. Use of Cytology, E6/E7 mRNA, and p16INK4a-Ki-67 to Define the Management of Human Papillomavirus (HPV)-Positive Women in Cervical Cancer Screening. , 2016, American journal of clinical pathology.
[28] L. Kalish,et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. , 1998, Epidemiology.